Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 12/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 10/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4936349 | 0.83 | CA2 (0.56) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL4936360 | 0.83 | CA2 (0.56) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL6348788 | 0.81 | HTR1A (0.56) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL5722925 | 0.81 | CA2 (0.55) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL6084492 | 0.81 | CA2 (0.59) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL1568273 | 0.81 | CA2 (0.55) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL1383106 | 0.81 | CA2 (0.59) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL14271049 | 0.81 | CA2 (0.55) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL6051185 | 0.81 | CA2 (0.55) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL936563 | 0.81 | CA2 (0.55) | CA2HTR1ASIGMAR1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-8791155-B2 | Chroman derivatives | EDISON PHARMACEUTICALS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS INC. | 2013-10-10 | — | — | US | disclosed |
| US-20120088783-A1 | CHROMAN DERIVATIVES | AMPERE LIFE SCIENCES, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8044097-B2 | Chroman derivatives | AMPERE LIFE SCIENCES, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-7875607-B2 | Neurodegenerative disorders; antiinflammatory agents; antiischemic agents; neuropathic pain; antiepileptic agents; Parkinson's disease; Alzheimer's disease; antidiabetic agents; 3-(6-Hydroxy-2-methyl-3,4,7,8,9,10-hexahydro-7,10-methano-2H -benzo[h]chromen-2-yl)-propionic acid methyl ester | AMPERE LIFE SCIENCES, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090192179-A1 | CHROMAN DERIVATIVES | EDISON PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090170814-A1 | 7,8-BICYCLOAKYL-CHROMAN DERIVATIVES | EDISON PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-7514461-B2 | Lipoxygenase moderators; autoimmune disease; neurodegenerative disease; respiratory system disorders; cardiovascular disorders; Alzheimer's disease; Parkinson's disease; amyotropic lateral sclerosis | EDISON PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7470798-B2 | Neurodegenerative disorders; antiinflammatory agents; strokes; antiischemic agents; neuropathic pain; brain disorders; antiepileptic agents; Parkinson's disease ; amyotropic lateral sclerosis; Alzheimer's disease; antidiabetic agents | EDISON PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20050065149-A1 | Neurodegenerative disorders; antiinflammatory agents; strokes; antiischemic agents; neuropathic pain; brain disorders; antiepileptic agents; Parkinson's disease ; amyotropic lateral sclerosis; Alzheimer's disease; antidiabetic agents | PTC THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
| US-20050065150-A1 | Lipoxygenase moderators; autoimmune disease; neurodegenerative disease; respiratory system disorders; cardiovascular disorders; Alzheimer's disease; Parkinson's disease; amyotropic lateral sclerosis | PTC THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | EDISON PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | disclosed |
| US-5756521-A | Chroman-2-ylmethylamino derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-05-26 | — | — | US | disclosed |
| US-5684039-A | Chroman-2-ylmethylamino derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-11-04 | — | — | US | disclosed |
| US-5670667-A | DOPAMINE INHIBITORS FOR PSYCHOLOGICAL DISORDERS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| US-5663194-A | SCHIZOPHRENIA | WYETH | 1997-09-02 | — | — | US | disclosed |
| EP-0787037-A1 | METHYL IODIDE AS A SOIL FUMIGANT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-08-06 | — | — | EP | disclosed |
| US-5541199-A | DOPAMINE MODULATORS, SCHIZOPHRENIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-07-30 | — | — | US | disclosed |
| WO-1996012559-A1 | METHYL IODIDE AS A SOIL FUMIGANT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088783-A1 | CHROMAN DERIVATIVES | CYP11B1, CYP11B2, TFAM | CA2 2734/4885HTR1A 498/4885SIGMAR1 2374/4885 |
| US-20090192179-A1 | CHROMAN DERIVATIVES | CYP11B1, CYP11B2, TFAM | CA2 2734/4885HTR1A 498/4885SIGMAR1 2374/4885 |
| US-20050065149-A1 | Neurodegenerative disorders; antiinflammatory agents; strokes; antiischemic agents; neuropathic pain; brain disorders; antiepileptic agents; Parkinson's disease ; amyotropic lateral sclerosis; Alzheimer's disease; antidiabetic agents | NLN, ACAA2, CS | CA2 1309/4885HTR1A 833/4885SIGMAR1 1014/4885 |
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | CLN6, LDHA, NLN | CA2 864/4885HTR1A 928/4885SIGMAR1 3676/4885 |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | CA2 1183/4885HTR1A 1006/4885SIGMAR1 4004/4885 |
| US-20050065150-A1 | Lipoxygenase moderators; autoimmune disease; neurodegenerative disease; respiratory system disorders; cardiovascular disorders; Alzheimer's disease; Parkinson's disease; amyotropic lateral sclerosis | ALOX12, ALOX15, ALOX15B | CA2 3612/4885HTR1A 429/4885SIGMAR1 3035/4885 |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | CA2 1183/4885HTR1A 1006/4885SIGMAR1 4004/4885 |
| US-20090170814-A1 | 7,8-BICYCLOAKYL-CHROMAN DERIVATIVES | COQ8A, TFAM, CS | CA2 2328/4885HTR1A 765/4885SIGMAR1 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.